India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US

Core Viewpoint - Indian drugmaker Lupin has settled a patent infringement dispute with Japan's Astellas Pharma regarding the bladder disorder drug Mirabegron, enabling Lupin to continue selling the product [1] Company Summary - Lupin has reached a settlement that allows it to maintain its market presence for Mirabegron, a drug used to treat bladder disorders [1] - The resolution of this dispute is significant for Lupin as it secures its ability to sell a key product without legal hindrances [1] Industry Summary - The settlement highlights ongoing patent disputes within the pharmaceutical industry, particularly concerning generic drug manufacturers and brand-name companies [1] - The outcome of such disputes can influence market dynamics and competition in the bladder disorder treatment segment [1]